MedTrace Logo

GSM (Genitourinary Syndrome Of Menopause) Management In Breast Cancer Survivors

NCT03185169 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2018-07-26

No results posted yet for this study

Summary

The impact of treatment for GSM on the quality of life will be examined for postmenopausal women (defined as last menstrual period \> 1 year ago or 6 months ago with FSH \>40) who have been diagnosed with breast cancer.

Conditions

Interventions

COMBINATION_PRODUCT

Replens and coconut oil

Sponsors & Collaborators

  • Alta Bates Summit Medical Center

    lead OTHER

Principal Investigators

  • Uma Suryadevara, MD · Alta Bates Summit Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-18
Primary Completion
2018-07-23
Completion
2018-07-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03185169 on ClinicalTrials.gov